Atlas market file · Equity · United States
Design Therapeutics, Inc.DSGN
- Last close
- 13.77
- Change
- +1.47%
- 96-bar range
- 9.87 – 17.25
- As of
- 6 Aug 2026
Design Therapeutics, Inc. is a pharmaceutical preparations issuer listed as DSGN on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
DSGN
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (+181.60% over the window).
Source rail: Yahoo Finance chart API (DSGN). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for DSGN. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
DSGN public profile
Pharmaceutical preparations issuer. Design Therapeutics, Inc. is connected to current market context, cited company sources and its retained research file.
Design Therapeutics, Inc. trades as DSGN on NASDAQ. Design Therapeutics, Inc. (DSGN) has a latest verified close of 13.77, up 1.47%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files DSGN under USA Stocks and Healthcare & Medicine Stocks for browsing.
What changed for Design Therapeutics, Inc. today
Design Therapeutics, Inc. (DSGN) is a biotech company focused on developing gene therapy products to treat rare genetic diseases. Despite its promising mission, the company’s financials paint a grim picture. In its latest 10-Q filing, Design Therapeutics reported $0 in revenues and a net income loss of $17.6 million. The company’s cash and cash equivalents stand at $12.8 million, but it’s burning through $16.4 million in operating activities. The company’s stockholders’ equity is $218.1 million, but with liabilities of $12.4 million, the financial health of the company is precarious.
Design Therapeutics’ core business is the development of gene therapy products, with a focus on rare genetic diseases. The company’s Phase 1/2 RESTORE-FA trial for Friedreich ataxia is a key part of its pipeline. The trial aims to assess safety, pharmacokinetics, pharmacodynamics, and exploratory clinical endpoints. The company’s research and development expenses are a significant $14.4 million, reflecting its commitment to advancing its gene therapy products. However, the company’s financials raise questions about its ability to sustain these efforts.
In its latest 10-Q filing, Design Therapeutics reported a net income loss of $17.6 million and operating income loss of $19.7 million. The company’s earnings per share are -$0.29, and its weighted average number of shares outstanding is 61.4 million. The company may also be required to pay royalties based on annual net product sales in the low single digits, with a minimum royalty of $0.1 million per calendar year. These financials highlight the challenges faced by biotech startups in turning a profit.
For more information on Design Therapeutics, Inc., you can visit the company’s SEC EDGAR filing index at https://www.sec.gov/edgar/browse/?CIK=1807120 or the company’s SEC submissions JSON at https://data.sec.gov/submissions/CIK0001807120.json. These sources provide detailed information on the company’s financials, filings, and other relevant data. The company’s SEC EDGAR 8-K filing from May 18, 2026, provides updates on the RESTORE-FA trial and other clinical developments.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
DSGN technical readout
Directional bias down. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on DSGN
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep DSGN research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
DSGN FAQ
What is Design Therapeutics, Inc. (DSGN)?Design Therapeutics, Inc. (DSGN) has a latest verified close of 13.77, up 1.47%, dated 6 Aug 2026. Use this page to check the price chart, company context,...
Design Therapeutics, Inc. (DSGN) has a latest verified close of 13.77, up 1.47%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for DSGN?Design Therapeutics, Inc. (DSGN) has a latest verified close of 13.77, up 1.47%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources,...
Design Therapeutics, Inc. (DSGN) has a latest verified close of 13.77, up 1.47%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files DSGN under USA Stocks and Healthcare & Medicine Stocks for browsing.
How often is the DSGN page updated?The DSGN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The DSGN public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for DSGN?The DSGN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:DSGN. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The DSGN file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:DSGN. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on DSGN?Yes. The workstation can open DSGN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open DSGN, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this DSGN page investment advice?No. The DSGN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The DSGN page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →